

Biotechnology and Competitive Advantage

Europe's Firms and the US Challenge

Edited by

Jacqueline Senker

Science Policy Research Unit, University of Sussex, UK

Coordinated by

Ronald van Vliet

Ministry of Economic Affairs, The Hague, The Netherlands



Edward Elgar

Cheltenham, UK • Northampton, MA, USA

Contents

<i>List of figures</i>	vi
<i>List of tables</i>	vii
<i>List of contributors</i>	viii
<i>List of abbreviations</i>	xi
1 Introduction <i>Ronald van Vliet</i>	1
2 Biotechnology: the external environment <i>Jacqueline Senker</i>	6
3 Industrial structure and the dynamics of knowledge generation in biotechnology <i>Pier Paolo Saviotti</i>	19
4 Risk perception, regulation and the management of agro-biotechnologies <i>Joanna Chataway and Gerald Assouline</i>	44
5 The creation of European dedicated biotechnology firms <i>Pier Paolo Saviotti, Pierre-Benoît Joly, Jacqueline Estades, Shyama Ramani and Marie-Angèle de Looze</i>	68
6 The evolution of European biotechnology and its future competitiveness <i>Rohini Acharya, Anthony Arundel and Luigi Orsenigo</i>	89
7 Biotechnology and Europe's chemical/pharmaceutical multinationals <i>Jacqueline Senker, Pierre-Benoît Joly and Michael Reinhard</i>	110
8 The 'commercialization gap' in gene therapy: lessons for European competitiveness <i>Paul Martin and Sandy Thomas</i>	130
9 Conclusions: biotechnology and European competitiveness <i>Rohini Acharya</i>	156
<i>Bibliography</i>	164
<i>Index</i>	173